Rosnilimab — Rheumatoid Arthritis

In Q3 2023, we initiated a global Phase 2 trial of rosnilimab for the treatment of moderate-to-severe rheumatoid arthritis

Top-line data is anticipated mid-year 2025

PD-1+ T cells broadly impact multiple clinically validated drivers of RA pathogenesis

>80% of T cells in RA synovium are PD-1+

  • Similar findings are observed in treatment naïve and biologic experienced patients

Adapted from Aletaha and Smolen, JAMA, 2018

Rosnilimab’s potent depletion and agonism reduces T cell proliferation and inflammatory cytokines that cause joint damage

Anti-CD3+ anti-CD28 stimulation of RA patient PBMCs for assessment of depletion and agonism MOA, representative data from N=8 donors
Two-way ANOVA, Tukey’s multiple comparison test. ****P<0.0001, ***p <0.001, **p <0.01, *p <0.05.
1. TNFa secretion measured in anti-CD3+ anti-CD28 stimulation of purified DC+T cells from N=4 healthy donors.